Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06719219 · ClinicalTrials.gov registry record · Phase 1
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
A Phase 1 study of Staphylococcus (S.) Aureus Infection, sponsored by LimmaTech Biologics.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 1
- Study location
NCT06719219 is a Phase 1 study of Staphylococcus (S.) Aureus Infection that has completed, run by LimmaTech Biologics. The registered enrollment target is 129 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06719219, a Phase 1 study of Staphylococcus (S.) Aureus Infection, has completed, sponsored by LimmaTech Biologics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL LTB-SA7
Study Locations (1)
Maryland
- Naval Medical Research Command Clinical Trial Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06719219
The ClinicalTrials.gov registry entry for NCT06719219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LimmaTech Biologics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcus (S.) Aureus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06719219 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06719219 about?
NCT06719219 is a clinical study titled "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.". In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
What is the current status of trial NCT06719219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2025-01-07. Estimated completion is 2026-03-04.
What conditions does trial NCT06719219 study?
This clinical trial studies the following conditions: Staphylococcus (S.) Aureus Infection.
What interventions are being tested in trial NCT06719219?
The interventions under investigation include: Placebo (BIOLOGICAL), LTB-SA7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06719219?
This trial is sponsored by LimmaTech Biologics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06719219 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.